Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcadia Biosciences (RKDA) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Arcadia Biosciences (RKDA) over the last 12 years, with Q3 2025 value amounting to -$1.2 million.

  • Arcadia Biosciences' Income from Continuing Operations rose 253.81% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.2 million, marking a year-over-year decrease of 27609.33%. This contributed to the annual value of -$4.3 million for FY2024, which is 1899.04% up from last year.
  • According to the latest figures from Q3 2025, Arcadia Biosciences' Income from Continuing Operations is -$1.2 million, which was up 253.81% from -$501000.0 recorded in Q2 2025.
  • In the past 5 years, Arcadia Biosciences' Income from Continuing Operations ranged from a high of $3.2 million in Q2 2023 and a low of -$13.8 million during Q4 2021
  • Over the past 5 years, Arcadia Biosciences' median Income from Continuing Operations value was -$2.3 million (recorded in 2022), while the average stood at -$3.0 million.
  • As far as peak fluctuations go, Arcadia Biosciences' Income from Continuing Operations skyrocketed by 18309.19% in 2023, and later plummeted by 79314.16% in 2024.
  • Quarter analysis of 5 years shows Arcadia Biosciences' Income from Continuing Operations stood at -$13.8 million in 2021, then skyrocketed by 76.96% to -$3.2 million in 2022, then surged by 85.79% to -$452000.0 in 2023, then crashed by 793.14% to -$4.0 million in 2024, then skyrocketed by 71.46% to -$1.2 million in 2025.
  • Its Income from Continuing Operations was -$1.2 million in Q3 2025, compared to -$501000.0 in Q2 2025 and $530000.0 in Q1 2025.